ИСТИНА

In connection with the emergence of new antibiotic resistant strains of bacteria in the world, the problem of treatment of sepsis has become more acute. One of the key tasks in the treatment of severe sepsis is the ability to remove bacterial endotoxins from the patient’s bloodstream. A high concentration of bacterial endotoxins in the human blood disrupts the normal functioning of the immune system and dramatically worsens the patient’s condition. The removal of endotoxins is carried out in extracorporeal therapy procedures using sorbents. Thus, the development of new effective sorbents for the removal of endotoxin is an important task. Lysozyme is able to bind with the components of the surface of a bacterial cell, so we have suggested that a lysozyme based sorbent can potentially be able to bind bacterial lipopolysaccharides. The sorbent made by us contains 14–15 mg of a covalently immobilized lysozyme per 1 g of an insoluble polysaccharide matrix (cross-linked agarose). This sorbent shows high efficiency of endotoxin binding from solution: 50 mL of sorbent can remove up to 88% Escherichia coli endotoxin or 84% Pseudomonas aeruginosa endotoxin from a 500 mL solution with an endotoxin concentration of 500 EU / mL (50 ng / mL).